Martin Rosenberg

Also serves as an adjunct professor of the bacteriology department at the University of Wisconsin. In 2001 retired as senior vice president of anti-infectives drug discovery and development at GlaxoSmithKline, where he spent a 20-year career. Formerly spent a 10-year career at the National Institutes of Health and served as a section chief of the National Cancer Institute. Formerly served as a member of the science advisory board of the Federal Drug Administration. Has published more than 200 papers and has more than 50 patents. Presently serves as editor-in-chief of Current Opinions in Biotechnology and as the section editor of the Journal of Bacteriology.

  • 2005 Second Quarter

Added to: Cubist Pharmaceuticals Inc. - Lexington, MA

Cubist researches and manufactures anti-infective products for the medical industry. Revenues are $754 million.